It’s a record! Biotech IPO fren­zy out­paces 2017 in half the time as 4 new ar­rivals on Nas­daq raise $556M

Be­tween one Boston-based biotech run by some vet­er­an stal­warts and two up­starts in the Bay Area, an ex­tend­ed hot streak of biotech IPOs has blast­ed past last year’s an­nu­al to­tal. And even as an­a­lysts cau­tion of a like­ly slow­down, we have one more IPO fil­ing to sug­gest that the in­dus­try may yet chal­lenge the high peak hit in 2014.

San Fran­cis­co-based Tri­ci­da $TC­DA may not be as well known as many of the bean town biotechs to go pub­lic this year, but it nev­er­the­less brought in a whop­ping $222 mil­lion haul on an up­sized of­fer­ing of shares that came it at $19 each — above the range.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER